ABCAM Plc Application for admission to trading (8982O)
November 10 2016 - 9:00AM
UK Regulatory
TIDMABC
RNS Number : 8982O
ABCAM Plc
10 November 2016
For immediate release 10 November 2016
ABCAM PLC
("Abcam" or "the Company)
Application for admission to trading
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the
supply of life science research tools, announces that further to
the acquisition of AxioMx, Inc. in November 2015 and the
acceleration of certain performance milestones announced earlier
today, an application has been made to AIM for the admission to
trading of 389,801 new ordinary shares of 0.2p each in the Company
each with voting rights. Admission is expected to take place on 16
November 2016.
Following the admission of the above shares, the Company's
issued ordinary share capital will comprise 203,477,510 ordinary
shares of 0.2p each with voting rights. This figure may be used by
shareholders as a denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, Abcam under the FCA's Disclosure and
Transparency Rules.
For further information please contact:
Abcam
+ 44 (0) 1223
Suzanne Smith, Company Secretary 696 000
J.P.Morgan Cazenove - Nominated + 44 (0) 20
Adviser & Corporate Broker 7742 4000
James Mitford / Chris Cargill
Notes for editors:
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's twelve locations are located in the world's leading life
science research hubs, enabling local services and multi-language
support. Founded in 1998 and headquartered in Cambridge, UK, the
Company sells to more than 100 countries. Abcam was admitted to AIM
in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSXBLFFQFFEFBD
(END) Dow Jones Newswires
November 10, 2016 09:00 ET (14:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024